Capricor Therapeutics (LTS:0HTB) Other Stockholders Equity: €0.00 Mil (As of Mar. 2026)


What is Capricor Therapeutics Other Stockholders Equity?

Capricor Therapeutics LTS:0HTB 37 Other Stockholders Equity is €0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0HTB with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

Capricor Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €0.00 Mil.

Capricor Therapeutics's quarterly Other Stockholders Equity declined from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil) but then increased from Dec. 2025 (€-0.00 Mil) to Mar. 2026 (€0.00 Mil).

Capricor Therapeutics's annual Other Stockholders Equity declined from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€-0.00 Mil) and declined from Dec. 2024 (€-0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Capricor Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Other Stockholders Equity Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 -0.00 -0.00 -0.00

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 -0.00 0.00

Capricor Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.00 Mil mean?
Capricor Therapeutics (LTS:0HTB) has a Other Stockholders Equity of €0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' Other Stockholders Equity too high?
Capricor Therapeutics' current Other Stockholders Equity is €0.00 Mil. Overall, Capricor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Other Stockholders Equity compare to COAG and DMRA?
Capricor Therapeutics' Other Stockholders Equity of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Capricor Therapeutics and its competitors. Capricor Therapeutics's current Other Stockholders Equity is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Capricor Therapeutics (LTS:0HTB) has a current Other Stockholders Equity of €0.00 Mil. The current Other Stockholders Equity is €0.00 Mil. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Capricor Therapeutics (LTS:0HTB), the current Other Stockholders Equity is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Capricor Therapeutics Business Description

Other Exchanges CAPR:USA4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.